QuatRx raises $44M in fifth venture finance round

QuatRx garnered $44 million in a new round of venture capital. The money is earmarked for the completion of a Phase III and Phase II study of its two endocrine programs. There's also an early-stage trial of a lipid-lowering compound. Venrock led the round. QuatRx has now raised $116 million in venture capital since 2000. The Ann Arbor, MI-based company had filed for an IPO last year but pulled it citing unfavorable market conditions.

- here's the report on QuatRx from Private Equity Hub

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.